Search results for " Drug"

showing 10 items of 3138 documents

Endothelium-dependent responses in human isolated thyroid arteries from donors

2004

The functional properties of the endothelium of human thyroid arteries remain unexplored. We investigated the intervention of nitric oxide (NO), prostacyclin (PGI(2)) and endothelium-derived hyperpolarizing factor (EDHF) in the responses to acetylcholine and noradrenaline in isolated thyroid arteries obtained from multi-organ donors. Artery rings were suspended in organ baths for isometric recording of tension. The contribution of NO, PGI(2) and EDHF to endothelium-dependent relaxation was determined by the inhibitory effects of N(G)-monomethyl-L-arginine (L-NMMA), indomethacin, and K(+) channel inhibitors respectively. Acetylcholine induced concentration-dependent relaxation; this effect w…

AdultMalemedicine.medical_specialtyCharybdotoxinCharybdotoxinEndotheliumEndocrinology Diabetes and MetabolismIndomethacinThyroid GlandProstacyclinNitric OxideApaminOuabainNitric oxideBiological FactorsNorepinephrinechemistry.chemical_compoundEndocrinologyCulture TechniquesInternal medicinePotassium Channel BlockersmedicineHumansomega-N-MethylarginineDose-Response Relationship DrugArteriesMiddle AgedEpoprostenolAcetylcholineEndocrinologymedicine.anatomical_structureApaminchemistryVasoconstrictioncardiovascular systemFemaleEndothelium VascularNitric Oxide SynthaseSodium-Potassium-Exchanging ATPasePeptidesAcetylcholinemedicine.drugArteryJournal of Endocrinology
researchProduct

The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study…

2010

Abstract Background Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time. Methods In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 13) or novel a…

AdultMalemedicine.medical_specialtyCognition disorderslcsh:RC435-571Teràpia cognitivamedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPilot ProjectsComorbidityCognitive therapyNeuropsychological TestsTrastorns de la cogniciólcsh:PsychiatryResearch articlemedicineHumansVerbal fluency testLongitudinal StudiesAntipsychotic drugsEffects of sleep deprivation on cognitive performancePsychiatryAntipsychoticRetrospective StudiesPsychiatric Status Rating ScalesCognitionExecutive functionsmedicine.diseasePsychiatry and Mental healthTreatment OutcomeSchizophreniaSchizophreniaFemaleSchizophrenic PsychologyAntipsicòticsEsquizofrèniaVerbal memoryCognition DisordersPsychologyAntipsychotic AgentsClinical psychologyBMC Psychiatry
researchProduct

Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms

2016

SummaryAim The aim of this study was to explore factors affecting efficacy of treatment of common cold symptoms with an over-the-counter ibuprofen/pseudoephedrine combination product. Methods Data from an anonymous survey among 1770 pharmacy customers purchasing the combination product for treatment of own common cold symptoms underwent post-hoc descriptive analysis. Scores of symptoms typically responsive to ibuprofen (headache, pharyngeal pain, joint pain and fever), typically responsive to pseudoephedrine (congested nose, congested sinus and runny nose), considered non-specific (sneezing, fatigue, dry cough, cough with expectoration) and comprising all 11 symptoms were analysed. Multiple…

AdultMalemedicine.medical_specialtyCommon ColdInfectious DiseaseIbuprofenNonprescription DrugsPharmacy030226 pharmacology & pharmacyDrug Administration Schedule03 medical and health sciences0302 clinical medicineExpedited Clinical TrialSurveys and QuestionnairesInternal medicinemedicineHumans030223 otorhinolaryngologyNosePain Measurementbusiness.industryAnti-Inflammatory Agents Non-SteroidalCommon coldmultiple regression analysisGeneral MedicinePseudoephedrinemedicine.diseaseIbuprofenPseudoephedrinesymptom scoreNasal decongestantNasal DecongestantsTreatment Outcomemedicine.anatomical_structureAnesthesiaJoint painDrug Therapy CombinationFemalemedicine.symptombusinessmedicine.drugCombination drugInternational Journal of Clinical Practice
researchProduct

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Inst…

2018

: Recommended strategy for venous thromboembolism (VTE) diagnosis includes the use of sensitive D-dimer (DDi) assays along with pretest probability (PTP) assessment. The Clinical and Laboratory Standards Institute (CLSI) recently issued a guideline (US FDA endorsed) on DDi in VTE exclusion. Such guideline specifies the ideal D-dimer assay characteristics and target population. Demonstrate STA-LiatestD-Di performance combined with a PTP score for proximal deep vein thrombosis (pDVT) exclusion in a CLSI compliant study. International, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard-of-care setting. DDi was measured in DVT-sus…

AdultMalemedicine.medical_specialtyDeep veinShort Communications030204 cardiovascular system & hematologySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsSTA-Liatest DDi03 medical and health sciences0302 clinical medicineInternal medicineOutpatientsD-dimermedicineHumansProspective StudiesProspective cohort studyexclusiondeep venous thrombosisAgedVenous ThrombosisUnited States Food and Drug Administrationbusiness.industryImmunoturbidimetryHematologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseThrombosisUnited StatesPulmonary embolismClinical trialPre- and post-test probabilitymedicine.anatomical_structureD-dimerFemalebusiness030215 immunologyBlood Coagulation & Fibrinolysis
researchProduct

Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience

2019

Abstract Aims In 2017 the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA) revised the criteria for access to therapy for patients with chronic hepatitis C as part of a three-year plan to eradicate HCV. We conducted a Delphi study to determine strategies to identify and treat patients with HCV and to develop through a shared pathway, a model to manage patient referral and optimize prescription center capacity with the overall aim of increasing access to therapy. Methods The process took place in two phases – Phase I (January 2017), before the criteria for treatment of HCV were revised and Phase II (May 2017) when AIFA developed a framework for the eradication of HCV infection in Ita…

AdultMalemedicine.medical_specialtyDelphi TechniqueGeneral PracticeDelphi methodDelphi methodAntiviral AgentsDrug PrescriptionsHealth Services AccessibilityMedication AdherencemodelsPatient referralTreatment targetsChronic hepatitismedicineHumansdelphi method; direct-acting antivirals; disease eradication; hepatitis c virus; adult; aged; antiviral agents; disease eradication; drug prescriptions; female; general practice; health care surveys; health services accessibility; hepatitis c chronic; humans; italy; male; medication adherence; middle aged; models theoretical; quality Improvement; referral and consultation; delphi techniquehepatitis cMedical prescriptiontheoreticalReferral and Consultationdirect-acting antiviralsAgedHepatitisdirect-acting antiviralHepatologyDisease Eradicationbusiness.industryHepatitis C virusGastroenterologyDrug agencyHepatitis C ChronicMiddle AgedModels Theoreticalmedicine.diseaseQuality ImprovementchronicItalyHealth Care SurveysFamily medicineFemaledisease eradicationbusiness
researchProduct

Dose-response relationships and plasma concentrations of digitalis glycosides in man.

1978

An inter-individual, randomized, double-blind study of digitoxin (Dt) and β-acetyl digoxin (D) was performed in 120 healthy male volunteers. Groups of 10 persons each received orally D 0, 0.1, 0.2, 0.3, 0.4, 0.5 or 0.6 mg and Dt 0.04, 0.08, 0.12, or 0.16 mg daily for 7 days; Loading doses were given for the first three days. Plasma levels were measured with an86Rb-erythrocyte assay 24 h after the last dose. ECG, carotid artery pulse and phonocardiogram were recorded prior to (b) and 24 h after (a) the last dose. QTc, amplitude of T-waves in V2 to V6, electromechanical systole (QS2c) and left ventricular ejection time (LVETc) were measured. The differences between a and b (Δ-values) reflect …

AdultMalemedicine.medical_specialtyDigoxinTime FactorsDigoxinDigitoxinQT intervalElectrocardiographyDigitoxinDouble-Blind MethodInternal medicinemedicineHumansPharmacology (medical)Pharmacologychemistry.chemical_classificationClinical Trials as TopicDose-Response Relationship DrugChemistryPulse (signal processing)GlycosideDigitalis GlycosidesHeartGeneral MedicinePlasma levelsEndocrinologySystolic time intervalsPlasma concentrationmedicine.drugEuropean journal of clinical pharmacology
researchProduct

Serum Concentrations of Fluvoxamine and Clinical Effects: A prospective open clinical trial

1998

This pilot study examined prospectively blood serum concentrations of fluvoxamine, side effects and therapeutic response after a fixed dosage of 100 mg fluvoxamine/day for 14 days. Twenty male and female patients who met the DSM-IV criteria of a major depression received 50 mg fluvoxamine b.i.d. for two weeks. On days 7 and 14 side effects and therapeutic response were registered and serum concentrations of fluvoxamine were determined. A Receiver Operating Characteristic (ROC) curve was constructed to determine a possible relationship between serum concentrations and clinical effects. The serum concentrations of fluvoxamine were highly variable, even when dosages were corrected for body wei…

AdultMalemedicine.medical_specialtyDosemedicine.medical_treatmentFluvoxamineGastroenterologyBlood serumInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesAgedAged 80 and overDepressive DisorderChemotherapymedicine.diagnostic_testReceiver operating characteristicbusiness.industryGeneral MedicineMiddle AgedClinical trialPsychiatry and Mental healthROC CurveFluvoxamineTherapeutic drug monitoringAnesthesiaAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Non-chemotherapy drug-induced agranulocytosis in a tertiary hospital

2015

Drug-induced agranulocytosis is a rare haematological disorder considered as severe adverse drug reaction. Due to its low incidence, the number of studies are low and the variability of clinical features and presentation in hospitalized patients is rarely described. Awe performed an observational, transversal and retrospective study in the haematology and toxicology unit in a tertiary hospital located in Spain (Valencia) (1996–2010) in order to assess its incidence, the drugs involved, the management and outcomes of drug-induced agranulocytosis. Twenty-one cases of agranulocytosis were retrieved. All of them presented severe and symptomatic agranulocytosis (fever and infection). The most c…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsItraconazoleHealth Toxicology and Mutagenesis030204 cardiovascular system & hematologyToxicologyTertiary Care CentersLeukocyte Count03 medical and health sciences0302 clinical medicineSulfasalazineInternal medicineGranulocyte Colony-Stimulating FactormedicineHumans030212 general & internal medicineAgedAged 80 and overbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseMetamizoleSpainAbsolute neutrophil countFemalebusinessCefuroximeAdverse drug reactionAgranulocytosismedicine.drugHuman & Experimental Toxicology
researchProduct

Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study.

2014

Abstract Background Drugs and herbal products can induce autoimmune hepatitis. We assessed frequency and clinical outcomes of patients suffering from drug-induced autoimmune hepatitis. Methods All patients with drug-induced liver injury admitted between 2000 and 2011 were retrospectively studied. Diagnoses of drug-induced autoimmune hepatitis and idiopathic autoimmune hepatitis were made according to simplified criteria. After discharge, all patients had regular follow-up and were contacted to update outcomes. Results Among 10,270 in-hospital patients, 136 (1.3%) were diagnosed with drug-induced liver injury. Among them, 12 (8.8%) were diagnosed as drug-induced autoimmune hepatitis (41.7% m…

AdultMalemedicine.medical_specialtyDrug-induced liver injuryAdolescentAutoimmunityAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyAutoimmunityYoung AdultInternal medicinemedicineHumansAutoimmunity; Drug-induced liver injury; Human leucocyte antigens; Liver biopsy --------------------------------------------------------------------------------Liver biopsy --------------------------------------------------------------------------------AgedRetrospective StudiesSettore MED/04 - Patologia GeneraleLiver injurySettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyGamma globulinRetrospective cohort studyHuman leucocyte antigenJaundiceMiddle Agedmedicine.diseaseHepatitis AutoimmuneTreatment OutcomeLiver biopsyCohortImmunologyFemalemedicine.symptomChemical and Drug Induced Liver InjurybusinessImmunosuppressive AgentsFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.

2005

Amisulpride is a clinically effective antipsychotic drug in a broad dose range with low propensity for extrapyramidal symptoms (EPS). Daily doses and plasma levels of amisulpride were analyzed within a large-scale therapeutic drug monitoring (TDM) survey to find plasma level ranges for optimized treatment under naturalistic conditions. Data of 378 schizophrenic patients treated with amisulpride (100-1550 mg) were included (40% female). Amisulpride plasma levels were analyzed at steady state; assessment comprised improvement (CGI-I) and side-effects, particularly EPS. For detection of cut-off values regarding non-response or EPS, receiver operating characteristics (ROC) curves were applied a…

AdultMalemedicine.medical_specialtyDyskinesia Drug-InducedAdolescentmedicine.drug_classStatistics as TopicAtypical antipsychoticPharmacologyGastroenterologyExtrapyramidal symptomsInternal medicineGermanymedicineHumansAmisulprideBiological PsychiatryAgedRetrospective StudiesAged 80 and overNeurologic ExaminationPsychiatric Status Rating ScalesReceiver operating characteristicmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryDopamine antagonistMiddle Agedmedicine.diseasePsychiatry and Mental healthDose–response relationshipROC CurveSchizophreniaTherapeutic drug monitoringSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridebusinessmedicine.drugAntipsychotic AgentsJournal of psychiatric research
researchProduct